- Home
- /
- Treatment
- /
- Page 106
Treatments
The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.
You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.
Become a Partner.
Country | Product | Indication | Sponsor | Date |
---|---|---|---|---|
Doxorubicin HCl with pluronic L-61 and pluronic F-127 | Esophageal carcinoma | Supratek Pharma Inc.;6100 Royalmount Avenue, Montreal;Quebec H4P 2R2 | October 7, 2005 | |
Dacetuzumab | Chronic lymphocytic leukemia | Seattle Genetics, Inc.;21823 30th Drive Southeast;Bothell, Washington, 98021 | October 6, 2005 | |
Brivaracetam | Symtomatic myoclonus | UCB Pharma, Inc.;1950 Lake Park Drive;Smyra, Georgia, 30080 | October 5, 2005 | |
Imatinib mesylate | Myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements | Novartis Pharmaceuticals Corporation;One Health Plaza, Mail Code 105/1E870D;East Hanover, New Jersey, 07936 | October 5, 2005 | |
Fenretinide | Neuroblastoma | USC-CHLA Institute for Pediatric Clinical Research;Childrens Hospital of Los Angeles, 4650 Sunset Blvd, MS 55;Los Angeles, California, 90027 | October 5, 2005 | |
Brivaracetam | Symtomatic myoclonus | UCB Pharma, Inc.;1950 Lake Park Drive;Smyra, GA, 30080 | October 5, 2005 | |
Buthionine sulfoxamine | Use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors | USC-CHLA Institute for Pediatric Clinical Research;Childrens Hospital of Los Angeles, 4650 Sunset Blvd, MS 55;Los Angeles, California, 90027 | October 5, 2005 | |
Buthionine sulfoxamine | Neuroblastoma | USC-CHLA Institute for Pediatric Clinical Research;Childrens Hospital of Los Angeles, 4650 Sunset Blvd, MS 55;Los Angeles, California, 90027 | October 5, 2005 | |
Chimeric monoclonal antibodies, c-alphaStx2 | For treatment of shiga-toxin producing bacterial infection | Taro Pharmaceuticals Inc.;130 East Drive;Brampton, Ontario | October 4, 2005 | |
Anti-tenascin 81C6 monoclonal antibody labeled w/ I 131 | Primary malignant brain tumors | Bradmer Pharmaceuticals, Inc.;9900 Corporate Campus Drive, Suite 3000;Louisville, Kentucky, 40223 | October 4, 2005 | |
Patupilone | Ovarian cancer | Novartis Pharmaceutical Corporation;One Health Plaza;East Hanover, New Jersey, 07936 | October 4, 2005 | |
Recombinant Human Interleukin-21 (rIL-21) | Stage II (T4), III or IV malignant melanoma | Zymo Genetics, Inc;1201 Eastlake Avenue East;Seattle, Washington, 98102 | October 4, 2005 | |
Enzastaurin | Glioblastoma | Denovo Biopharma LLC;6331 Nancy Ridge Drive;San Diego, California, 92121 | September 19, 2005 | |
Masitinib | Mastocytosis | AB Science;3, avenue George V; | September 14, 2005 | |
Imatinib mesylate | Systemic mastocytosis | Novartis Pharmaceuticals Corporation;One Health Plaza, Mail Code 105/1E870D;East Hanover, New Jersey, 07936 | September 9, 2005 | |
Imatinib mesylate | Idiopathic hypereosinophilic syndrome | Novartis Pharmaceuticals Corporation;One Health Plaza, Mail Code 105/1E870D;East Hanover, New Jersey, 07936 | August 25, 2005 | |
Recombinant Epstein-Barr virus gp350 glycoprotein vaccine | Prevention of post-transplantation lymphoproliferative disorders in pediatric recipients of solid-organ transplantation | Henogen S.A.;Rue des Professeurs Jenner et Brachet, 12, B-6041-Gosselies; | August 18, 2005 | |
Recombinant anti-CD40 monoclonal antibody | Chronic lymphocytic leukemia | Novartis Pharmaceutical Corporation;Oncology Business Unit, One Health Plaza, Bldg 104;East Hanover, New Jersey, 07936 | August 12, 2005 | |
Balsalazide disodium | Ulcerative colitis | Salix Pharmaceuticals, Inc.;400 Somerset Corporate Blvd;Bridgewater, New Jersey, 08807 | August 12, 2005 | |
Alfentanil | Painful HIV-associated neuropathy | Cinergen, LLC;146 Medinah Drive;Blue Bell, Pennsylvania, 19422 | August 9, 2005 | |
Rapamycin (mTOR) inhibitor | Bone sarcoma | Merck Sharp & Dohme Corp.;S Merck & Co., Inc. Subsidiary, P. O. Box 1000, UG-2C50;North Wales, Pennsylvania, 19454 | August 9, 2005 | |
Biocarbonate infusate | Use in the management of patients undergoing continuous renal replacement therapy with hemofiltration | Dialysis Solutions, Inc.;14 Emmett Place, Whitby, Ontario L1R 2B4; | August 9, 2005 | |
Capsaicin | Postherpetic neuralgia | TheraQuest Biosciences, LLC;146 Medinah Drive;Blue Bell, Pennsylvania, 19422 | August 3, 2005 | |
Edotreotide | Somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors | Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary);777 Old Saw Mill River Road;Tarrytown, New York, 10591 | July 28, 2005 | |
Nucleic acid aptamer binding to tumor cell nucleon | Renal cancer | Antisoma Inc.;300 Technology Square;Cambridge, Massachusetts | July 28, 2005 |